A multinational survey assessing the impact and burden of pruritus on patients with primary sclerosing cholangitis
Rattachement africain : us, il. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Pruritus is a common primary sclerosing cholangitis (PSC) symptom that greatly impacts quality of life (QoL; sleep, fatigue) and, in severe cases, may be an indication for liver transplantation. Currently, there are no effective pruritus treatments for PSC. This survey focuses on the presentation/severity of pruritus in PSC and on the participants' perspective of the broader burden on QoL. METHODS: A multinational survey was conducted over 8 months with individuals diagnosed with PSC. A 36-item questionnaire focused on the pruritus severity scale (0, no itch; 10, worst itch imaginable) and impact on QoL was posted on approved websites; data were collected anonymously and analyzed using descriptive statistics. RESULTS: Of the 482 respondents, 91% and 34% had experienced and were currently experiencing pruritus, respectively. The median worst pruritus score was 6, and 45% (74 of 164) reported the pruritus episode lasted ≥1 month. Pruritus was associated with a higher degree of sleep disturbance and worsening fatigue. In half of those who reported pruritus, the symptom led to disruption of daily activities. Twenty-two percent of participants reported missing work or school. Pruritus negatively impacted mood changes in >50% of respondents. Most commonly used pruritus treatments were antihistamines, ursodeoxycholic acid, cholestyramine, topical creams/ointments, and rifampin. Forty-nine percent reported using ≥2 medications, and of those, 75% experienced "only partial" or "no relief." CONCLUSIONS: Cholestatic pruritus in PSC has a major adverse impact on QoL, interferes with daily activities, and is inadequately treated in the majority of respondents. These unmet needs highlight the importance of developing safe/effective antipruritic treatments for PSC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A multinational survey assessing the impact and burden of pruritus on patients with primary sclerosing cholangitis
- Date Crossref
- 12/02/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Washington State University Spokane pays non établi dans la noticeUniversité ou école supérieure
-
Liver Institute Northwest pays non établi dans la noticeÉtablissement de santé
-
Georgia Highlands College pays non établi dans la noticeUniversité ou école supérieure
-
PSC Partners Seeking a Cure pays non établi dans la noticeOrganisation à but non lucratif
-
Israel Medical Association pays non établi dans la noticeInstitution
-
Elson S. Floyd College of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
PSC Support pays non établi dans la noticeInstitution
-
Hetz: The Israeli Association for the Health of the Liver pays non établi dans la noticeOrganisation à but non lucratif
-
Inc. Mirum Pharmaceuticals pays non établi dans la noticeEntreprise
Washington State University Spokane, Liver Institute Northwest et Georgia Highlands College, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.